The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:1914680358a341dc988921ed0c680bc4]
Lilly Clinical Trial Registry
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer [clinicaltrials_resource:1914680358a341dc988921ed0c680bc4]
Lilly Clinical Trial Registry
Bio2RDF identifier
1914680358a341dc988921ed0c680bc4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1914680358a341dc988921ed0c680bc4
measure [clinicaltrials_vocabulary:measure]
The primary objective is to co ...... r metastatic colorectal cancer
description
Lilly Clinical Trial Registry
identifier
clinicaltrials_resource:1914680358a341dc988921ed0c680bc4
title
The primary objective is to co ...... r metastatic colorectal cancer
@en
type
label
The primary objective is to co ...... 4680358a341dc988921ed0c680bc4]
@en